Advanced Biomed

Leadership changed in April 2026 with the appointment of Xiaomin Chen as CEO and chairman, concurrent with the Acellent HK acquisition; the former CTO resigned in March 2026. While the new team may bring AI experience, there is no public track record yet of creating shareholder value at scale, and the strategy has shifted materially away from the company’s IPO thesis.

Governance remains constrained by micro‑cap financing needs.